Last reviewed · How we verify
Fertility Center of Las Vegas — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cabergoline Pill | Cabergoline Pill | marketed | Dopamine D2 receptor agonist | Dopamine D2 receptor | Endocrinology / Reproductive Medicine |
Therapeutic area mix
- Endocrinology / Reproductive Medicine · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
- University of North Carolina, Chapel Hill · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Fertility Center of Las Vegas:
- Fertility Center of Las Vegas pipeline updates — RSS
- Fertility Center of Las Vegas pipeline updates — Atom
- Fertility Center of Las Vegas pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Fertility Center of Las Vegas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fertility-center-of-las-vegas. Accessed 2026-05-17.